DK1109571T3 - Fremgangsmåde til behandling af saltafhængig hypertension - Google Patents

Fremgangsmåde til behandling af saltafhængig hypertension

Info

Publication number
DK1109571T3
DK1109571T3 DK99968631T DK99968631T DK1109571T3 DK 1109571 T3 DK1109571 T3 DK 1109571T3 DK 99968631 T DK99968631 T DK 99968631T DK 99968631 T DK99968631 T DK 99968631T DK 1109571 T3 DK1109571 T3 DK 1109571T3
Authority
DK
Denmark
Prior art keywords
dependent hypertension
treating salt
methods
compositions
treating
Prior art date
Application number
DK99968631T
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Univ Washington
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Scios Inc filed Critical Univ Washington
Application granted granted Critical
Publication of DK1109571T3 publication Critical patent/DK1109571T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99968631T 1998-09-09 1999-09-09 Fremgangsmåde til behandling af saltafhængig hypertension DK1109571T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27

Publications (1)

Publication Number Publication Date
DK1109571T3 true DK1109571T3 (da) 2004-06-21

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99946776T DK1112083T3 (da) 1998-09-09 1999-09-09 Behandling af mikrovaskulære angiopatier
DK99968631T DK1109571T3 (da) 1998-09-09 1999-09-09 Fremgangsmåde til behandling af saltafhængig hypertension

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK99946776T DK1112083T3 (da) 1998-09-09 1999-09-09 Behandling af mikrovaskulære angiopatier

Country Status (13)

Country Link
US (3) US6352975B1 (da)
EP (2) EP1109571B1 (da)
JP (2) JP2002532382A (da)
AT (2) ATE253934T1 (da)
AU (2) AU5910599A (da)
BR (2) BR9913564A (da)
CA (2) CA2340728C (da)
DE (2) DE69912815T2 (da)
DK (2) DK1112083T3 (da)
ES (2) ES2211165T3 (da)
IL (2) IL141687A0 (da)
PT (2) PT1112083E (da)
WO (2) WO2000013702A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211165T3 (es) * 1998-09-09 2004-07-01 Scios Inc. Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
WO2001032695A2 (en) * 1999-11-02 2001-05-10 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
EP1427323A4 (en) * 2001-08-20 2004-09-15 Univ Virginia USE OF S-NITROSOTHIOL SIGNALING TO TREAT BREATH CONTROL DISORDERS
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
BRPI0610499A2 (pt) * 2005-04-12 2010-06-22 Intradigm Corp moléculas de ácido nucléico , composições e usos das referidas moléculas
US8440619B2 (en) * 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
ES2600781T3 (es) * 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
EP3600251A4 (en) 2017-03-30 2021-01-13 Wake Forest University Health Sciences METHOD OF TREATMENT OF KIDNEY DISEASE
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
JP3549202B2 (ja) 1989-03-24 2004-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内皮細胞成長因子、その分離および発現
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
JP2001503755A (ja) * 1996-11-01 2001-03-21 ユーロジーン・リミテッド Ｎｏまたはプロスタサイクリン産生を刺激する薬剤の治療的使用およびデリバリー装置
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ES2211165T3 (es) * 1998-09-09 2004-07-01 Scios Inc. Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.

Also Published As

Publication number Publication date
EP1112083A2 (en) 2001-07-04
AU6028599A (en) 2000-03-27
AU5910599A (en) 2000-03-27
WO2000013703A9 (en) 2000-06-02
JP2002532382A (ja) 2002-10-02
IL141687A0 (en) 2002-03-10
DE69915310T2 (de) 2005-03-10
ATE253934T1 (de) 2003-11-15
US6352975B1 (en) 2002-03-05
ES2216630T3 (es) 2004-10-16
EP1109571B1 (en) 2004-03-03
IL141686A0 (en) 2002-03-10
ES2211165T3 (es) 2004-07-01
BR9913533A (pt) 2001-06-05
US20040224885A1 (en) 2004-11-11
EP1109571A2 (en) 2001-06-27
BR9913564A (pt) 2001-05-22
WO2000013703A2 (en) 2000-03-16
US20020193288A1 (en) 2002-12-19
WO2000013702A2 (en) 2000-03-16
EP1112083B1 (en) 2003-11-12
PT1109571E (pt) 2004-05-31
DE69915310D1 (de) 2004-04-08
ATE260675T1 (de) 2004-03-15
DK1112083T3 (da) 2004-03-08
WO2000013702A3 (en) 2000-09-08
CA2340728C (en) 2007-11-27
WO2000013702A9 (en) 2000-10-19
PT1112083E (pt) 2004-03-31
DE69912815D1 (de) 2003-12-18
WO2000013703A3 (en) 2000-07-06
DE69912815T2 (de) 2004-10-21
CA2340320C (en) 2006-11-14
CA2340728A1 (en) 2000-03-16
JP2002524421A (ja) 2002-08-06
CA2340320A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
DK1109571T3 (da) Fremgangsmåde til behandling af saltafhængig hypertension
DK1202724T3 (da) Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
BR9707819A (pt) Imunogenos peptidicos
DK1231887T3 (da) Fremgangsmåde og sammensætning til behandling af ar
DK0912535T3 (da) Konjugater af cis-docosahexaensyre og paclitaxel
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
DK0914116T3 (da) Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
DK1144474T3 (da) Vandig reaktiv spartelmasse
DE69813898D1 (de) Substituierte porphyrinen
PT1322696E (pt) Composicoes que compreendem um notroxido, um promotor e eventualmente um iniciador de radicais livres
TR199701669A1 (xx) Deri preparasyonu i�in bile�imler.
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
DK0967987T3 (da) Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
DE69627702D1 (de) Stabilisierte, korrosionsinhibierte feuerhemmende zusammensetzungen und methoden
WO2002063003A3 (en) Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
DK0880569T3 (da) Kompositioner til behandling af jord, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
DK1303294T3 (da) Fremgangsmåde til behandling af instabil angina pectoris
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
PT950056E (pt) N-(piridinilamino) isoindolinas e compostos relacionados
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein